These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
178 related articles for article (PubMed ID: 31286100)
1. Posaconazole-Induced Hypertension Due to Inhibition of 11 Thompson GR; Beck KR; Patt M; Kratschmar DV; Odermatt A J Endocr Soc; 2019 Jul; 3(7):1361-1366. PubMed ID: 31286100 [TBL] [Abstract][Full Text] [Related]
2. Molecular mechanisms of posaconazole- and itraconazole-induced pseudohyperaldosteronism and assessment of other systemically used azole antifungals. Beck KR; Telisman L; van Koppen CJ; Thompson GR; Odermatt A J Steroid Biochem Mol Biol; 2020 May; 199():105605. PubMed ID: 31982514 [TBL] [Abstract][Full Text] [Related]
3. Mineralocorticoid hypertension and hypokalaemia induced by posaconazole. Boughton C; Taylor D; Ghataore L; Taylor N; Whitelaw BC Endocrinol Diabetes Metab Case Rep; 2018; 2018():. PubMed ID: 29472988 [TBL] [Abstract][Full Text] [Related]
4. Posaconazole-induced hypertension and hypokalemia due to inhibition of the 11β-hydroxylase enzyme. Barton K; Davis TK; Marshall B; Elward A; White NH Clin Kidney J; 2018 Oct; 11(5):691-693. PubMed ID: 30289132 [TBL] [Abstract][Full Text] [Related]
5. Unravelling drug-induced hypertension: molecular mechanisms of aldosterone-independent mineralocorticoid receptor activation by posaconazole. Sanchez-Niño MD; Ortiz A Clin Kidney J; 2018 Oct; 11(5):688-690. PubMed ID: 30289131 [TBL] [Abstract][Full Text] [Related]
7. Apparent Mineralocorticoid Excess in the Pediatric Population: Report of a Novel Pathogenic Variant of the 11β-HSD2 Gene and Systematic Review of the Literature. Adamidis A; Cantas-Orsdemir S; Tsirka A; Abbott MA; Visintainer P; Tonyushkina K Pediatr Endocrinol Rev; 2019 Mar; 16(3):335-358. PubMed ID: 30888125 [TBL] [Abstract][Full Text] [Related]
9. Hormonal hypertension in children: 11beta-hydroxylase deficiency and apparent mineralocorticoid excess. Cerame BI; New MI J Pediatr Endocrinol Metab; 2000; 13(9):1537-47. PubMed ID: 11154148 [TBL] [Abstract][Full Text] [Related]
10. Impaired protein stability of 11beta-hydroxysteroid dehydrogenase type 2: a novel mechanism of apparent mineralocorticoid excess. Atanasov AG; Ignatova ID; Nashev LG; Dick B; Ferrari P; Frey FJ; Odermatt A J Am Soc Nephrol; 2007 Apr; 18(4):1262-70. PubMed ID: 17314322 [TBL] [Abstract][Full Text] [Related]
11. Molecular biology of 11β-hydroxylase and 11β-hydroxysteroid dehydrogenase enzymes. White PC; Pascoe L; Curnow KM; Tannin G; Rösler A J Steroid Biochem Mol Biol; 1992 Dec; 43(8):827-35. PubMed ID: 22217826 [TBL] [Abstract][Full Text] [Related]
12. 11beta-hydroxysteroid dehydrogenase and its role in the syndrome of apparent mineralocorticoid excess. White PC Am J Med Sci; 2001 Dec; 322(6):308-15. PubMed ID: 11780688 [TBL] [Abstract][Full Text] [Related]
13. Apparent mineralocorticoid excess in a Brazilian kindred: hypertension in the heterozygote state. Li A; Li KX; Marui S; Krozowski ZS; Batista MC; Whorwood CB; Arnhold IJ; Shackleton CH; Mendonca BB; Stewart PM J Hypertens; 1997 Dec; 15(12 Pt 1):1397-402. PubMed ID: 9431844 [TBL] [Abstract][Full Text] [Related]
14. A mutation in the cofactor-binding domain of 11beta-hydroxysteroid dehydrogenase type 2 associated with mineralocorticoid hypertension. Odermatt A; Dick B; Arnold P; Zaehner T; Plueschke V; Deregibus MN; Repetto H; Frey BM; Frey FJ; Ferrari P J Clin Endocrinol Metab; 2001 Mar; 86(3):1247-52. PubMed ID: 11238516 [TBL] [Abstract][Full Text] [Related]